Efficacy of furosemide in patients with chronic kidney disease with residual renal functions in hemodialysis and non-hemodialysis patients

Introduction and aim. Chronic kidney disease (CKD) affects kidney function, characterized by albuminuria or reduced estimat ed glomerular filtration rate (eGFR), and is influenced by factors such as etiology, pathogenesis, intensity, and progression. Ac cording to data from the literature, the efficacy of furosemide has not been much researched much in CKD patients. The study evaluates the efficacy in chronic kidney disease patients, regardless of hemodialysis, and compares its diuretic effect based on the administration route. Material and methods. A prospective observational study was conducted in a tertiary healthcare facility for 6 months (October 2021 to March 2022). 100 CKD patients who met the criteria were enrolled in the study. Data on study-relevant parameters, such as route of administration (ROA), hemodialysis frequency, hospital stay, blood urea, serum creatinine, sodium, and potas sium, were collected. Pearson’s chi-square test was used to evaluate the association between parameters. One-way ANOVA was applied to analyze the significant association between ROA and urine output. Results. Of all the study samples, 72% received intravenous furosemide and 28% received furosemide orally. There was a sig nificant difference in eGFR and urine output on admission and discharge days. There was an increase in urine output when the patient received furosemide and improvement in eGFR was found. A significant association was also observed between systolic blood pressure, sodium, and potassium. Conclusion. The study found no significant differences in furosemide efficacy in CKD patients, regardless of ROA, hospital stay, or frequency of hemodialysis, indicating similar effectiveness.